Group discussion between colleagues


We continue to partner with others to access the best science and accelerate the development of new medicines in both small molecules and biologics. We are active in building early stage biotech and academic alliances alongside in-licensing and acquisitions to strengthen our pipeline and broaden the range of treatment options for physicians and patients.

Open Innovation is increasingly a way of life at AstraZeneca. By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and non-profit organisations, we can accelerate new ideas into innovative medicines. Creating a more permeable research environment also makes good business sense – reducing risk and leveraging scarce resources effectively.


Videos: Collaborating with AstraZeneca

Shaun Grady, Shaun Grady, VP Strategic Partnering & Business Development

In an interview for PharmaTV, AstraZeneca’s VP Strategic Partnering and Business Development, Shaun Grady, discusses our partnering strategy at the BioPartnering Europe conference.

Watch this video


Our overall goal at BIO was to continue to raise the profile of AstraZeneca to ensure we’re differentiating ourselves as the preferred partner to do business with.

Shaun Grady, VP Strategic Partnering & Business Development